Methods and uses for treating anhedonia
AssigneeXenon Pharmaceuticals Inc.
InventorSimon Neil Pimstone
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Claims36
A method of treating anhedonia, comprising administering a therapeutically effective amount of Compound A to a human in need thereof;
- wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.
A method of reversing hyperactivity in the ventral tegmental area (VTA, comprising administering an effective amount of Compound A to a human in need thereof;
- wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide;
- and
- wherein the human is suffering from anhedonia.
Dependencies are inferred from the claim text.